Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Horner syndrome secondary to otomastoiditis.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus·2025

Same author

Retrobulbar hemorrhage after tenecteplase thrombolysis for acute stroke following strabismus surgery.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus·2025

Same author

ICU-Broncho-Aspiration Protocols Monitoring at an Academic Health Network System.

Southern medical journal·2025

Same author

The Biological Clock of Liver Metabolism in Metabolic Dysfunction-Associated Steatohepatitis Progression to Hepatocellular Carcinoma.

Biomedicines·2024

Same author

Patterns of Gene Expression, Splicing, and Allele-Specific Expression Vary among Macular Tissues and Clinical Stages of Age-Related Macular Degeneration.

Cells·2023

Same author

A systems biology approach uncovers novel disease mechanisms in age-related macular degeneration.

Cell genomics·2023

Search research articles

Related Experiment Video

Updated: May 21, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Pembrolizumab Associated Bilateral Optic Neuritis.

Robert Finley¹, Praveen Jeyaseelan¹

¹Department of Ophthalmology, West Virginia University, Morgantown, West Virginia, USA.

Ocular Immunology and Inflammation

|May 20, 2026

Summary

A rare vision-threatening side effect of pembrolizumab, drug-induced bilateral optic neuropathy, was effectively managed with plasmapheresis. This immune-related adverse event highlights the need for vigilant monitoring of patients receiving immune checkpoint inhibitors.

Keywords:

Bilateral optic neuritis immune check point inhibitors monoclonal antibody pembrolizumab vision loss

Related Experiment Videos

Last Updated: May 21, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Area of Science:

Oncology
Neurology
Immunology

Background:

Immune checkpoint inhibitors like pembrolizumab are increasingly used for various cancers.
Adverse events, including immune-related adverse events (irAEs), can occur and require careful management.
Ocular and neurological complications are potential irAEs associated with these therapies.

Purpose of the Study:

To report a rare, vision-threatening side effect of pembrolizumab therapy.
To describe the effective management of drug-induced bilateral optic neuritis.
To emphasize the importance of considering drug-induced optic neuropathy in cancer patients with vision loss.

Main Methods:

A case report detailing a patient's experience.
Review of the patient's medical history and treatment course.
Documentation of the diagnostic process and therapeutic interventions.

Main Results:

A 52-year-old female patient developed bilateral optic neuritis while on pembrolizumab for vulvar squamous cell carcinoma.
The optic neuritis was attributed to an altered immune response secondary to pembrolizumab targeting the nervous system.
The patient did not respond to intravenous steroids but showed good visual recovery after plasmapheresis.

Conclusions:

Drug-induced bilateral optic neuropathy is a rare but serious complication of pembrolizumab therapy.
Vigilant monitoring for irAEs is crucial as immune checkpoint inhibitors gain wider use.
Plasmapheresis can be an effective treatment for managing this specific adverse event, leading to visual recovery.